【US Stock Market Movement】Grail surges on September 24: FDA support and early screening with Galleri

Grail September 24 Surge Analysis

Keywords: FDA support, Galleri early screening

1. On September 23, 2026, the Medical Devices Advisory Committee of the US FDA determined by a vote of 7 to 2 that the benefits of GRAIL's Galleri multi-cancer early detection product outweigh the risks; safety received 10 out of 10 support, and efficacy received 6 out of 4 support.

2. On September 23, 2026, GRAIL's Galleri, by using AI to analyze cfDNA methylation patterns in blood, can screen for more than 50 types of cancer, with a specificity as high as 99.85% and a positive predictive value of about 77%. The product's regulatory review has made key progress.

(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)